Recital 156, Decision_act (EU) 2018/9019

In forcesince 29 Oct 2018

The Commission notes that post-Transaction, through its ownership of

VetFamily, Mars would obtain knowledge about its competitors' pricing (and other competitively sensitive information also) to VetFamily clinics i.e. Mars' downstream competitors. As a result, and in line with what is described above in relation to the customer foreclosure concerns, Mars could subsequently adapt its commercial strategy to undermine any attempt by competitors to sell to [40-50]% of the market that would be controlled by Mars post-Transaction (i.e. Anicura's and VetFamily clinics). This is likely to put competitors at a competitive disadvantage, thereby dissuading them to enter or expand in the market.